Candidate host epigenetic marks predictive for HIV reservoir size, responsiveness to latency reversal, and viral rebound
Michael J Corley, Alina PS Pang, Thomas A Rasmussen, Martin Tolstrup, Ole S Sogaard, Lishomwa C Ndhlovu
AIDS | LIPPINCOTT WILLIAMS & WILKINS | Published : 2021
OBJECTIVE: This study aimed to identify candidate host epigenetic biomarkers predicting latency reversal agents (LRA) efficacy and HIV-1 rebound kinetics during analytical treatment interruption (ATI). DESIGN: Retrospective longitudinal epigenetic profiling study from 13 people with HIV (PWH) on virologically suppressive antiretroviral therapy (ART) that participated in a LRA (HDAC inhibitor) clinical trial (NCT01680094) and a subsequent optional ATI to monitor for viral recrudescence after ART cessation. METHODS: Genome-wide DNA methylation (DNAm) in purified CD4+ T cells was measured at single-nucleotide resolution using the Infinium MethylationEPIC array. HIV-1 DNA and RNA measures were p..View full abstract
Awarded by National Institutes of Health (NIH)
This research was supported by core facilities supported in part by National Institutes of Health (NIH) grants P30CA071789. L.C.N. receives support in part from the National Institutes of Health (NIH) grants R01 MH112457 and R01 AG063846. M.J.C. receives support from NIH Grants K01 HL140271 and R01 AG063846. The data from this study was submitted to the NCBI Gene Expression Omnibus (GEO) http://www.ncbi.nlm.nih.gov/geo/.